Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.

Ma YL, Zeng QQ, Chiang AY, Burr D, Li J, Dobnig H, Fahrleitner-Pammer A, Michalská D, Marin F, Pavo I, Stepan JJ

Bone20 Nov 2013Cited by 60 (Europe PMC)

PMID24269280DOI10.1016/j.bone.2013.11.011PepBankPUB-24269280

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis patients, endocortical unlabeled biopsies decreased after teriparatide.
In plain wordsIn women with osteoporosis, fewer biopsies lacked endocortical labeling after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseEndocortical unlabeled biopsies
Study
n = 45
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928001
02HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis patients, periosteal unlabeled biopsies decreased after teriparatide.
In plain wordsIn women with osteoporosis, fewer biopsies lacked periosteal labeling after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePeriosteal unlabeled biopsies
Study
n = 45
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928002
03HumanNon-randomized trialEfficacy outcome
In alendronate-pretreated women with osteoporosis, quiescent osteons decreased after teriparatide.
In plain wordsIn women previously given alendronate, inactive bone units decreased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseQuiescent osteons after prior alendronate
Study
n = 29
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928003
04HumanNon-randomized trialEfficacy outcome
In alendronate-pretreated women with osteoporosis, forming osteons increased after teriparatide.
In plain wordsIn women previously given alendronate, bone-forming units increased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseForming osteons after prior alendronate
Study
n = 29
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928004
05HumanNon-randomized trialEfficacy outcome
In alendronate-pretreated women with osteoporosis, resorbing osteons increased after teriparatide.
In plain wordsIn women previously given alendronate, bone-resorbing units increased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseResorbing osteons after prior alendronate
Study
n = 29
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928005
06HumanNon-randomized trialEfficacy outcome
In alendronate-pretreated women with osteoporosis, teriparatide increased endocortical mineral apposition rate.
In plain wordsIn women previously given alendronate, mineral deposition increased at the inner bone surface after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical mineral apposition rate
Study
n = 29
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Teriparatide treatment resulted in significant increases of MAR in the endocortical, and MS/BS% in the periosteal compartment in the ALN-pretreated group.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928006
07HumanNon-randomized trialEfficacy outcome
In alendronate-pretreated women with osteoporosis, teriparatide increased periosteal mineralizing surface.
In plain wordsIn women previously given alendronate, the mineralizing outer bone surface increased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeriosteal mineralizing surface
Study
n = 29
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Teriparatide treatment resulted in significant increases of MAR in the endocortical, and MS/BS% in the periosteal compartment in the ALN-pretreated group.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928007
08HumanNon-randomized trialEfficacy outcome
In alendronate-pretreated women with osteoporosis, endocortical wall width increased after teriparatide.
In plain wordsIn women previously given alendronate, inner bone wall width increased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical wall width after prior alendronate
Study
n = 29
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Endocortical wall width was increased in both ALN-pretreated and TN groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928009
09HumanNon-randomized trialEfficacy outcome
In alendronate-pretreated women with osteoporosis, cortical porosity increased after teriparatide.
In plain wordsIn women previously given alendronate, outer bone porosity increased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical porosity
Study
n = 29
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Cortical porosity and cortical thickness were significantly increased in the ALN-pretreated group after teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928011
10HumanNon-randomized trialEfficacy outcome
In alendronate-pretreated women with osteoporosis, cortical thickness increased after teriparatide.
In plain wordsIn women previously given alendronate, outer bone thickness increased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical thickness
Study
n = 29
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Cortical porosity and cortical thickness were significantly increased in the ALN-pretreated group after teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928012
11HumanNon-randomized trialEfficacy outcome
In treatment-naïve women with osteoporosis, endocortical wall width increased after teriparatide.
In plain wordsIn women without prior treatment, inner bone wall width increased after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical wall width in treatment-naïve women
Study
n = 16
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24monthsAs given in this study (human).
Source sentences
Summary
Endocortical wall width was increased in both ALN-pretreated and TN groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
Report a problemFND-2426928010

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

12HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
After teriparatide, most bone formation indices remained lower in alendronate-pretreated women than in treatment-naïve women.
In plain wordsAfter teriparatide, most bone formation measures remained lower with prior alendronate than without prior treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone formation indices by prior treatment
Study
n = 45
Comparator
Treatment-naïve women receiving teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Most indices of bone formation remained lower in the ALN-pretreated group compared with the TN group at study end.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN).
Summary · context
Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24months of teriparatide treatment.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2426928008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.